Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
1996 |
| gptkbp:ATCCode |
gptkb:M03BX02
|
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:drugClass |
gptkb:muscle_relaxant
|
| gptkbp:form |
gptkb:tablet
capsule |
| gptkbp:genericName |
gptkb:tizanidine
|
| gptkbp:halfLife |
2.5 hours
|
| http://www.w3.org/2000/01/rdf-schema#label |
Zanaflex
|
| gptkbp:interactsWith |
gptkb:fluvoxamine
ciprofloxacin |
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Acorda_Therapeutics
|
| gptkbp:mechanismOfAction |
gptkb:alpha-2_adrenergic_agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
drowsiness hypotension dry mouth |
| gptkbp:usedFor |
muscle spasticity
|
| gptkbp:bfsParent |
gptkb:tizanidine
|
| gptkbp:bfsLayer |
8
|